Disitamab Vedotin Production Cost Reports

The report provides a detailed analysis essential for establishing a disitamab vedotin production plant. It encompasses all critical aspects necessary for disitamab vedotin production, including the cost of disitamab vedotin production, disitamab vedotin plant cost, disitamab vedotin production costs, and the overall disitamab vedotin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a disitamab vedotin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Disitamab vedotin, also known as RC48 or Aidixi, is a HER2-targeted antibody-drug conjugate (ADC) used in pharmaceutical applications to treat HER2-positive cancers. It is developed by RemeGen and approved in China since 2021 for HER2-overexpressing (IHC2+ or 3+) locally advanced or metastatic gastric cancer after at least two prior chemotherapy regimens. It comprises a humanised anti-HER2 monoclonal antibody linked via a cleavable valine-citrulline (VC) linker to the cytotoxic payload monomethyl auristatin E (MMAE), enabling targeted delivery, lysosomal cleavage, and a bystander effect for heterogeneous tumours. Its clinical data show promising efficacy across indications like urothelial carcinoma (ORR ~50%, PFS 5.9 months), HER2-positive/low breast cancer (ORR 25-31%, DCR 73-83%), and ongoing trials for non-small cell lung, oesophageal, and gynaecological cancers, with manageable side effects such as leukopenia and alopecia. It has been licensed globally to Seagen/Pfizer for further development.

The market growth for disitamab vedotin is driven by its growing demand in the oncology sector. Its first approval in China in 2021 for HER2-positive gastric cancer, followed by expansions to urothelial carcinoma and breast cancer indications, boosts the market growth due to the high unmet needs in advanced solid tumours with limited treatment options. Additionally, strong clinical data showing objective response rates of 25-70% across HER2-low and high expressions fuel the market expansion. Moreover, investor confidence, fuelled by the ADC market's explosive growth, driven by technological advances like its cleavable linker and bystander effect, enhances efficacy and safety over competitors like trastuzumab deruxtecan. Ongoing global trials, FDA breakthrough designations, and real-world evidence of tolerability further accelerate adoption, while pipeline expansions into lung, oesophageal, and combination therapies with PD-1 inhibitors position it for broader revenue potential. Industrial disitamab vedotin procurement is influenced by regulatory approvals, and inclusion in national treatment guidelines which dictates eligibility and access, limiting procurement to approved oncology centres treating HER2-positive gastric, urothelial, or breast cancers.

Raw Material for Disitamab Vedotin Production

According to the disitamab vedotin production plant project report, the various raw materials for disitamab vedotin production include Chinese hamster ovary cells.

Production Process of Disitamab Vedotin

The extensive disitamab vedotin production cost report consists of the following major industrial production process:

1. Production via recombinant expression: The production process of disitamab vedotin starts by first producing the novel humanised IgG1 monoclonal antibody (disitamab or hertuzumab) with enhanced HER2 binding and internalisation via recombinant expression in mammalian cells like Chinese hamster ovary cells (CHO). The process is followed by partial reduction of interchain disulfide bonds using TCEP to expose cysteinyl thiols. The reduced antibody is conjugated site-specifically to monomethyl auristatin E via a protease-cleavable mc-vc-PABC linker through maleimide-thiol chemistry, targeting a drug-to-antibody ratio (DAR) of 3.5-4.5. The final purification employs hydrophobic interaction chromatography (HIC) and size-exclusion chromatography (SEC) to isolate the homogeneous ADC, free of aggregates and unconjugated components, before lyophilisation into a stable solid formulation.

Disitamab vedotin (RC48), a HER2-targeted antibody-drug conjugate, consists of a humanised IgG1 monoclonal antibody (hertuzumab) covalently linked via a protease-cleavable mc-vc linker to monomethyl auristatin E (MMAE) with an average drug-to-antibody ratio of ~4. It appears as a white to light yellow solid stored at 4 degree Celsius protected from light. It possesses linear pharmacokinetics with half-lives of ~30 hours for the intact ADC and ~60 hours for released MMAE. It has site-specific conjugation at cysteinyl residues for plasma stability and lysosomal cleavage by cathepsin B to yield tubulin-inhibiting MMAE (IC50 ~1 nM).